BRN2 and MITF together impact AXL expression in melanoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The inverse relationship between Microphthalmia-associated Transcription Factor (MITF) and AXL receptor tyrosine kinase is crucial in melanoma.
• AXL^high/MITF^low melanoma tumors are associated with therapeutic resistance.
• A distinct cell population with extremely high AXL expression, negative/low for MITF and BRN2, exists within melanoma tumors.

Purpose of the Study:

• To investigate the role of transcription factors MITF and BRN2 in regulating AXL expression in melanoma.
• To identify potential therapeutic targets for melanoma relapse associated with AXL expression.

Main Methods:

• Depletion of MITF and BRN2 in cultured melanoma cell lines.
• Analysis of AXL expression levels following transcription factor depletion.
• Re-expression of BRN2 to assess its effect on AXL levels.

Main Results:

• Depleting both MITF and BRN2 significantly increased AXL expression compared to MITF depletion alone.
• Re-expression of BRN2 decreased AXL expression, independent of MITF levels.
• Identified a melanoma cell population characterized by high AXL and low MITF/BRN2.

Conclusions:

• BRN2 plays a significant role in regulating AXL expression in melanoma, independent of MITF.
• The AXL^high/MITF^low/BRN2^low cell population may be responsible for melanoma therapy resistance and relapse.
• These cells represent potential therapeutic targets for overcoming melanoma treatment failure.